Characterization of 22RV1-Luc xenograft response to androgen-deprivation therapy.

Katie O'Donovan, Heather Nesbitt, Stephanie McKeown, Nicole Camac, Declan McKenna

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Original language	English
Title of host publication	Unknown Host Publication
Publisher	Keystone Symposia on Molecular and Cellular Biology
Number of pages	100
Publication status	Published - May 2015
Event	2015 Keystone Symposia Conference E3: Hypoxia: From Basic Mechanisms to Therapeutics - Dublin, Ireland Duration: 1 May 2015 → …

Conference	2015 Keystone Symposia Conference E3: Hypoxia: From Basic Mechanisms to Therapeutics
Period	1/05/15 → …

Cite this

O'Donovan, K., Nesbitt, H., McKeown, S., Camac, N., & McKenna, D. (2015). Characterization of 22RV1-Luc xenograft response to androgen-deprivation therapy. In Unknown Host Publication Keystone Symposia on Molecular and Cellular Biology.

@inproceedings{e45d170829fe436e915d96b455408680,

title = "Characterization of 22RV1-Luc xenograft response to androgen-deprivation therapy.",

keywords = "22RV1, hypoxia, prostate tumour",

author = "Katie O'Donovan and Heather Nesbitt and Stephanie McKeown and Nicole Camac and Declan McKenna",

year = "2015",

month = may,

language = "English",

booktitle = "Unknown Host Publication",

publisher = "Keystone Symposia on Molecular and Cellular Biology",

address = "United States",

note = "2015 Keystone Symposia Conference E3: Hypoxia: From Basic Mechanisms to Therapeutics ; Conference date: 01-05-2015",

}

TY - GEN

T1 - Characterization of 22RV1-Luc xenograft response to androgen-deprivation therapy.

AU - O'Donovan, Katie

AU - Nesbitt, Heather

AU - McKeown, Stephanie

AU - Camac, Nicole

AU - McKenna, Declan

PY - 2015/5

Y1 - 2015/5

KW - 22RV1

KW - hypoxia

KW - prostate tumour

M3 - Conference contribution

BT - Unknown Host Publication

PB - Keystone Symposia on Molecular and Cellular Biology

T2 - 2015 Keystone Symposia Conference E3: Hypoxia: From Basic Mechanisms to Therapeutics

Y2 - 1 May 2015

ER -